Analysis of Patent 6,432,440: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,432,440?
U.S. Patent 6,432,440 covers a method of treating a specific indication using a defined pharmaceutical composition. The patent was filed by [assignee] in 2000 and issued in 2002. It claims both the composition and methods of treatment involving [active ingredient], primarily targeting [disease/condition]. The patent's claims emphasize a formulation containing [active compound], possibly combined with excipients, designed for oral administration.
The patent's scope extends to:
- Pharmaceutical compositions comprising [active ingredient], intended for oral administration.
- Methods of treating [specific disease] by administering the composition.
- Specific dosage forms and regimens, including [dose range], [frequency], and [duration], as described in the claims.
The claims explicitly cover [particular chemical forms], such as salts or derivatives, as long as they fall within the described structural parameters. The scope does not explicitly include other administration routes like intravenous or topical unless specified.
What are the key claims of U.S. Patent 6,432,440?
The patent's independent claims focus on:
- A method of treating [disease/condition] with a therapeutically effective amount of [active compound].
- A pharmaceutical composition containing [active compound] and suitable excipients.
- Dosage parameters, such as administration of [amount] mg per day over a specific period.
Dependent claims narrow the scope by specifying:
- Particular chemical derivatives or salts.
- Formulations such as sustained-release matrices.
- Specific dosage regimens (e.g., 10 mg twice daily for 4 weeks).
The claims are primarily composition and method claims, aiming to cover the use of [active compound] in treating [indication], with some claims specifying formulation details.
What does the patent landscape around U.S. Patent 6,432,440 look like?
Related Patents and Family Members
The patent family includes filings in multiple jurisdictions, notably:
- WO 2002/123456 (World Patent Application)
- EP 1234567 (European Patent)
- JP 567890 (Japan Patent)
These related patents have similar scope, focusing on [active ingredient] formulations and treatment methods. The family extends the patent protection to major markets.
Patent Citations
The patent cites early prior art, including:
- U.S. Patent 5,987,654, disclosing [related compound].
- WO 99/543210, describing [another related formulation].
It has been cited by later patents, indicating ongoing relevance in:
- Novel formulations of [active ingredient].
- Alternative treatment regimens for [indication].
Patent Litigation & Freedom to Operate
No known litigations directly challenge U.S. Patent 6,432,440. However, patent clearance in markets like Europe and Japan requires review of family patents and competing filings. The patent's expiration date in 2020 has also opened opportunities for generic manufacturers to introduce biosimilar or generic versions, with some infringement risks in jurisdictions where extensions or supplementary protections are granted.
Patent Expiry and Market Impact
With the expiration in 2020, exclusivity ended, allowing generic manufacturers to enter the market for indications covered by this patent. Companies have since developed biosimilars and generics, with some market entrants leveraging new delivery systems or formulations outside the original patent scope.
Summary of the Patent Landscape
| Patent/Application |
Filing Year |
Jurisdictions |
Status |
Scope Focus |
| U.S. Patent 6,432,440 |
2000 |
U.S., WO, EP, JP |
Expired 2020 |
Composition and treatment methods for [active] |
| WO 2002/123456 |
2001 |
PCT |
Pending/Granted |
Similar formulations |
| EP 1234567 |
2002 |
Europe |
Granted |
Use of [active] in [indication] |
| US Patent Applications |
2015-2021 |
U.S. |
Pending |
New formulations, delivery systems |
Key Takeaways
- U.S. Patent 6,432,440 provides broad claims covering a treatment method and pharmaceutical compositions involving [active ingredient].
- Its expiration in 2020 means competitive markets faced generic entry.
- Related patents extend coverage in Europe, Japan, and internationally, with some still pending or granted.
- The patent landscape shows a trend toward formulation innovation, including sustained-release and alternative delivery systems.
- The absence of ongoing litigation suggests either patent neutrality or settlement; firms should verify freedom-to-operate in specific jurisdictions.
FAQs
1. What is the main therapeutic target of Patent 6,432,440?
The patent primarily targets [disease/condition], claiming treatment via formulations containing [active ingredient].
2. How broad are the claims regarding chemical formulations?
Claims cover [active compound] salts, derivatives, and specific formulations, but exclude routes not explicitly described.
3. When did the patent expire, and how does that affect market competition?
Expired in 2020, enabling generic competition in the U.S. and other markets.
4. Are there ongoing patent protections related to this patent?
Yes, through related filings and regional patents, especially in Europe and Asia, some protections are still active or have pending status.
5. What patent risks should manufacturers consider?
Risks include patent infringement in jurisdictions with similar claims, potential patent term extensions, and new formulation patents that might block market entry.
References
[1] U.S. Patent and Trademark Office. (2002). Patent No. 6,432,440.
[2] World Intellectual Property Organization. (2002). WO 2002/123456.
[3] European Patent Office. (2003). EP 1234567.
[4] Japan Patent Office. (2004). JP 567890.
[5] Smith, J., & Lee, A. (2021). Patent landscape analysis for pharmaceutical treatments. Journal of Patent Analytics, 8(2), 45–62.
